What Drugs Cause Neutropenia and What Are the Signs?

Dozens of commonly prescribed medications can cause neutropenia, a drop in the white blood cells that serve as your body’s front-line defense against bacterial and fungal infections. The list spans chemotherapy drugs, certain antibiotics, antipsychotics, antithyroid medications, anti-seizure drugs, and even some anti-inflammatory painkillers. The signs tend to be deceptively ordinary at first: a sore throat, mouth ulcers, fever, or an infection that seems disproportionately severe. Because the condition can develop silently before symptoms appear, understanding which drugs carry the risk and what to watch for matters more than most people realize.

How Neutropenia Is Defined

Neutrophils are the most abundant type of white blood cell, and they act as rapid responders when bacteria or fungi enter the body. Your bone marrow churns out billions of them every day, partly because they are remarkably short-lived, circulating in the blood for only about six to eight hours before being replaced.¹ That constant production means anything that disrupts the bone marrow or accelerates neutrophil destruction can cause counts to plummet quickly.

Neutropenia is diagnosed when your absolute neutrophil count falls below 1,500 cells per microliter of blood. Mild neutropenia sits between 1,000 and 1,500, moderate between 500 and 1,000, and severe below 500.² The risk of serious infection climbs steeply once counts drop below 500, and below 100 the danger becomes acute. Counts naturally fluctuate throughout the day with exercise, stress, and even time of day, so a single borderline reading does not always mean trouble.

How Drugs Lower Neutrophil Counts

Not every drug causes neutropenia in the same way. The mechanism matters because it influences how fast the problem develops, how severe it gets, and how quickly you recover once the drug is stopped.

The most straightforward route is direct bone marrow suppression. Chemotherapy drugs are the most familiar culprits here. Because cancer drugs target rapidly dividing cells, they inevitably damage the precursor cells in the bone marrow that give rise to neutrophils. The result is a predictable dip in neutrophil counts, typically bottoming out around day 10 to 14 after a dose before gradually recovering.³ This pattern is so well established that oncology teams plan chemotherapy cycles around it. That said, marrow suppression from chemotherapy can trigger cascading problems: infections, fevers, anemia, and delays in treatment that may compromise outcomes.⁴

A second mechanism involves maturation arrest. The bone marrow may keep producing early-stage neutrophil precursors, but those cells get stuck partway through development and never mature into functioning neutrophils that can enter the bloodstream. Certain antibiotics, including vancomycin and beta-lactams, have been linked to this pattern. In one reported case, vancomycin caused a striking buildup of immature cells in the bone marrow while the mature neutrophil count in the blood collapsed.⁵ A study of beta-lactam-induced severe neutropenia found that bone marrow exams most often showed this kind of maturation arrest or outright aplasia of the neutrophil lineage.⁶

A third mechanism is immune-mediated destruction, where the drug triggers the body’s own immune system to attack circulating neutrophils. This has been proposed as the explanation for many idiosyncratic reactions, in which a patient who has been tolerating a drug for weeks or months suddenly develops severe neutropenia with no warning. An immune mechanism involving drug-specific antibodies is frequently suggested for these cases, though strong supporting evidence remains limited.⁷

Which Drug Classes Carry the Highest Risk

Beyond chemotherapy, the drugs most strongly associated with neutropenia fall into several broad categories. The risk varies enormously: some drugs cause mild, transient dips in a large share of patients, while others cause life-threatening agranulocytosis in a small but unpredictable minority.

• Antithyroid drugs: Medications like methimazole and propylthiouracil, used to treat overactive thyroid, have long been recognized as notable offenders. The risk of agranulocytosis has been estimated at roughly 3 per 10,000 users.⁸
• Clozapine: This antipsychotic, considered uniquely effective for treatment-resistant schizophrenia, carries enough risk that it requires mandatory blood monitoring in most countries. When combined with sodium valproate, another psychiatric medication, the odds of developing neutropenia roughly double.⁹
• Antibiotics: Vancomycin and certain beta-lactam antibiotics (especially ceftriaxone and cloxacillin) are the most common antibiotic culprits in patients receiving prolonged intravenous therapy. In one large retrospective study, vancomycin caused neutropenia in about 4% of patients, ceftriaxone in about 2%, and cloxacillin in about 2%.¹⁰ A systematic review of case reports also identified vancomycin and ceftaroline as the two most commonly described antibiotic causes.¹¹
• Anti-seizure drugs: Carbamazepine is the most frequently cited example. In one published case, a patient who had been stable on carbamazepine for three years developed severe white blood cell depletion along with fever, weight loss, and swollen lymph nodes, all of which resolved after the drug was stopped.¹²
• Other notable drugs: Ticlopidine (an older antiplatelet agent), sulfasalazine (used in inflammatory bowel disease and rheumatoid arthritis), dipyrone (a painkiller widely used outside the US), diclofenac, spironolactone, and sulfamethoxazole-trimethoprim have all been associated with the condition.¹³

Biologic therapies, the newer class of drugs used for autoimmune diseases, can also cause transient mild-to-moderate neutropenia. Drugs targeting tumor necrosis factor, interleukin-6, and certain immune-cell surface markers have shown roughly a 10% rate of mild neutropenia in some reports.

Recognizing the Signs

The frustrating reality is that neutropenia itself has no symptoms. You cannot feel that your neutrophil count is low. What you can feel are the consequences: infections that your body can no longer fight off effectively. This means the first sign is often a problem that seems unrelated to the medication.

Fever is the most important early warning sign. In someone with a very low neutrophil count, a fever above 38.3°C (about 101°F) is treated as a medical emergency until proven otherwise. The infection source may be obvious, like a skin wound that turns red and swollen, or it may be hidden. Pneumonia and bloodstream infections are common in severe cases, and roughly two-thirds of hospitalized patients with deeply low counts develop serious infections including pneumonia, bloodstream infections, or septic shock.

Mouth and throat problems show up frequently. Painful mouth ulcers, sore throats, and swollen, inflamed gums are classic early clues. These develop because the lining of the mouth is naturally exposed to bacteria, and without enough neutrophils to keep those bacteria in check, the tissue breaks down. A clinical evaluation for neutropenia should assess symptoms including recurrent infections, fever, and mucosal ulcerations.¹⁴

Skin infections, perianal abscesses, and urinary tract infections are also common presentations. What makes drug-induced neutropenia particularly tricky is that the usual signs of infection can be muted. Pus, for instance, is largely made of dead neutrophils, so a person with very few neutrophils may have an infected wound that doesn’t produce the expected swelling or pus. The infection looks less dramatic than it actually is, which can delay diagnosis.

Who Is at Higher Risk

Not everyone taking these medications develops neutropenia. Several factors tilt the odds.

Age is one of the strongest. Older adults develop idiosyncratic drug-induced neutropenia more often than younger people, partly because of natural age-related declines in bone marrow reserve and partly because they tend to take more medications simultaneously.¹⁵ Female sex has also been identified as a risk factor, though the reasons are not fully understood.

Kidney function plays a role, especially with chemotherapy. A study of patients receiving a specific oral chemotherapy regimen found that those with moderately impaired kidney function had a roughly 24% higher rate of severe neutropenia and a significantly higher rate of the most dangerous grade compared to patients with better kidney function.¹⁶ The explanation is straightforward: impaired kidneys clear drugs more slowly, leading to higher and longer drug exposure in the bone marrow.

Genetics matter in specific situations. The clearest example involves clozapine. Genome-wide studies have identified specific immune-system gene variants that strongly predict who will develop clozapine-induced agranulocytosis. Two regions in the major histocompatibility complex, involving the HLA-DQB1 and HLA-B genes, are independently linked to the risk.¹⁷ A meta-analysis further confirmed that a particular variant, HLA-DRB1*04:02, was a significant predictor, though it had high specificity but low sensitivity, meaning it is better at ruling people in than ruling people out.¹⁸ These findings are not yet used for routine screening in most clinical settings, but the research points toward a future in which genetic testing could spare some patients from unnecessary monitoring or steer them away from drugs their immune system is likely to react against.

How It Is Diagnosed

A simple blood draw is all it takes to confirm neutropenia. The standard complete blood count with differential gives the absolute neutrophil count directly. When a patient on a known offending drug develops unexplained fever or infections, this test is the first step.

If the neutropenia is severe or the cause is not immediately obvious, additional workup follows. A peripheral blood smear lets a pathologist look at the shape and maturity of the remaining white cells under a microscope, which can reveal whether the problem is in production or destruction. Bone marrow biopsy is reserved for cases that are severe, persistent, or unexplained. In drug-induced cases, the bone marrow often looks either hyperplastic (overproducing immature cells that aren’t maturing) or normocellular, as opposed to the maturation arrest seen in congenital forms.¹⁴

Sorting out the cause of neutropenia can be genuinely challenging. Infections themselves (especially viral infections), autoimmune diseases, nutritional deficiencies, and bone marrow cancers can all lower neutrophil counts. When someone is on multiple medications simultaneously, pinpointing the specific drug responsible sometimes requires stopping one medication at a time and watching for recovery. In the retrospective study of antibiotic-induced cases, when a beta-lactam was identified as the culprit, switching to a structurally different beta-lactam led to full recovery of the neutrophil count in every case where it was tried.¹⁰

Treatment and Recovery

The single most important step in drug-induced neutropenia is stopping the offending drug. In most non-chemotherapy cases, counts begin to recover within days to a couple of weeks after discontinuation. The speed of recovery depends on the mechanism: direct marrow suppression may take longer to resolve than immune-mediated destruction, because the bone marrow needs time to regenerate its neutrophil-producing capacity.

For patients who develop fever while severely neutropenic, immediate broad-spectrum antibiotics are the standard of care, even before the source of infection is identified. Waiting for culture results in a patient with almost no immune defenses is too risky.

In chemotherapy settings, a growth factor called G-CSF (granulocyte colony-stimulating factor) is widely used to speed neutrophil recovery. Filgrastim and its longer-acting cousin pegfilgrastim stimulate the bone marrow to produce neutrophils faster and are approved for preventing chemotherapy-induced neutropenia.¹⁹ These drugs are sometimes also used off-label in severe non-chemotherapy drug-induced neutropenia when the count is dangerously low and infection has set in, though the evidence base for that use is thinner.

Monitoring Requirements for Clozapine

Clozapine deserves its own discussion because the monitoring system built around it is unlike anything else in psychiatry. In the United States, the Clozapine Risk Evaluation and Mitigation Strategy (REMS) program requires registered pharmacies, prescribers, and patients to participate in a structured blood monitoring protocol before clozapine can be dispensed.²⁰ The intent is patient safety, but the program’s administrative complexity has created real barriers to access, sometimes leaving the most treatment-resistant patients unable to receive the most effective medication available to them.

There is growing momentum to relax some of these requirements. A recent global consensus study recommended lowering the threshold at which clinicians should consider stopping clozapine, from the current level down to a neutrophil count of 1,000 (and even lower, to 500, for individuals with Duffy-null phenotype, a normal genetic variant common in people of African descent that causes constitutionally lower neutrophil counts). The same consensus recommended discontinuing routine blood monitoring after two years of stable treatment.²¹ Whether regulatory agencies will adopt these recommendations remains to be seen, but the trend in expert opinion is clearly toward less burdensome monitoring.

Levamisole-Adulterated Cocaine

One of the more unusual and underrecognized causes of drug-induced neutropenia has nothing to do with prescription medications. Levamisole, a veterinary deworming agent, has been found as a common adulterant in illicit cocaine. Estimates suggest that more than three-quarters of cocaine users in the United States are exposed to it.²² A meaningful fraction of those exposed develop autoimmune-mediated neutropenia, along with skin lesions and other complications.

The first confirmed case report in the US described a previously healthy man who came to the emergency department with five days of mouth pain and was found to have a neutrophil count of just 19 cells per microliter, far below the normal minimum of 1,500. Testing confirmed levamisole in both his urine and the residue in his crack pipe.²³ In another case, a patient’s neutropenia resolved within four days of stopping cocaine use, further supporting the link.²⁴

This is worth knowing about because the presentation can easily be misdiagnosed. A patient who arrives with severe neutropenia, mouth ulcers, and perhaps purplish skin lesions may not volunteer their cocaine use, and clinicians who aren’t thinking about levamisole may pursue an extensive and expensive workup for autoimmune or hematologic disease before the real cause comes to light. Emergency physicians and hematologists have become increasingly aware of this pattern, but it remains a diagnostic blind spot in some settings.

When Timing Provides a Clue

The timeline between starting a drug and developing neutropenia varies in ways that can be diagnostically helpful. Chemotherapy-induced neutropenia is the most predictable: counts dip around 10 to 14 days after a dose and recover over the following one to two weeks, depending on the specific agent. Oncologists use this predictable pattern to time blood draws and decide when G-CSF support is needed.

Non-chemotherapy drug reactions are less predictable. Some develop within the first few weeks of treatment, but others, like the carbamazepine case described earlier, appear only after months or years of stable use. Antibiotic-induced neutropenia tends to emerge after extended courses, typically beyond two weeks of intravenous therapy, which is why it shows up most often in patients receiving prolonged courses for conditions like bone infections or endocarditis. The idiosyncratic nature of these reactions means there is no reliable way to predict exactly when they will strike, which is part of what makes them dangerous. The only real safeguard for high-risk drugs is regular blood monitoring, and for everything else, clinical vigilance when a patient on any of these medications develops unexplained fever or infections.